Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nelonemdaz
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nelonemdaz (neu2000KWL) is a multi-target neuroprotectant acting as both a moderate NR2B-selective NMDA receptor antagonist and a potent spin trapper that ameliorates both fast NMDA receptor-mediated neuronal death and the delayed free-radical mediated b...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 19, 2022
Lead Product(s) : Nelonemdaz
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Salfaprodil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 10, 2021
Lead Product(s) : Salfaprodil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nelonemdaz
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In this study, the addition of nelonemdaz to surgical blood clot removal improved a patient’s chances of returning to functional independence 90 days later.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 14, 2020
Lead Product(s) : Nelonemdaz
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Salfaprodil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Samsung Medical Center | Chonnam National University Hospital | Gangnam Severance Hospital | Kyungpook National University Hospital | Pusan National University Hospital | Soonchunhyang University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Antioxidant and NMDA Receptor Blocker Wins Anoxic Brain Damage of KorEa OHCA Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 29, 2018
Lead Product(s) : Salfaprodil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Samsung Medical Center | Chonnam National University Hospital | Gangnam Severance Hospital | Kyungpook National University Hospital | Pusan National University Hospital | Soonchunhyang University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Salfaprodil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 13, 2016
Lead Product(s) : Salfaprodil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable